BioSpace News Archive

Mirati Therapeutics, Inc.® presented two-year follow-up data from a pooled analysis of the Phase 1/1b Cohort and Phase 2 Cohort A for the KRYSTAL-1 study evaluating adagrasib in patients with non-small cell lung cancer harboring a KRASG12C mutation.

Alcon, the global leader in eye care dedicated to helping people see brilliantly, revealed final data from its Vivity® Registry Study, which monitored real-world patient experiences for up to 12 months post cataract surgery with implantation of either AcrySof® IQ Vivity® or AcrySof® IQ Vivity® Toric presbyopia-correcting intraocular lens.

Bristol Myers Squibb announced results from a Phase 2 study evaluating BMS-986278, a potential first-in-class, oral, lysophosphatidic acid receptor 1 antagonist in patients with progressive pulmonary fibrosis.

Zevra Therapeutics, Inc., a rare disease therapeutics company, announced a poster presentation featuring study data that underscores the cardiovascular safety profile of serdexmethylphenidate, the sole active pharmaceutical ingredient in KP1077, Zevra’s investigational candidate for the treatment for idiopathic hypersomnia, at the Psych Congress 2023 taking place September 6-10, 2023, in Nashville, Tennessee.

Supernus Pharmaceuticals, Inc. announces the presentation of two posters at Psych Congress 2023 with new data showing improved efficacy in children ages 6 years and older with ADHD when Qelbree is added to a stimulant, as well as in adults with ADHD who undergo long-term treatment with Qelbree.

Castle Biosciences, Inc. announced data from a study showing the addition of drug-drug interactions and lifestyle factors to drug-gene interactions provided by its IDgenetix® test significantly impacted the number of drug recommendations and contributed to improved remission rates for patients with moderate to severe depression.